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Abstract
Background. Malignant peripheral nerve sheath tumor (MPNST) is an aggressive and poorly understood malignant neoplasm. Even in the setting of multimodal therapy, the clinical course of MPNST is frequently marked by
metastatic conversion and poor overall prognosis, with optimal treatment paradigms for this rare tumor unknown.
Methods. We reviewed the medical records and histopathology of 54 consecutive patients who were treated at
University of California San Francisco between 1990 and 2018.
Results. Our cohort consisted of 24 male and 30 female patients (median age 38 years). Fédération Nationale
des Centres de Lutte Contre Le Cancer (FNCLCC) sarcoma grading criteria segregated patients into groups with
differences in overall survival (OS) (P = .02). Increasing Ki-67 labeling index was associated with poor OS (hazard
ratio [HR] 1.36 per 10%, P = .0002). Unsupervised hierarchical clustering-based immunohistochemical staining
patterns identified 2 subgroups of tumors with differences in H3K27me3, Neurofibromin, S100, SOX10, p16, and
EGFR immunoreactivity. In our cohort, cluster status was associated with improved locoregional failure-free rate
(P = .004) in response to radiation.
Conclusions. Our results lend support to the FNCLCC sarcoma grading criteria as a prognostic scheme for MPNST,
although few cases of grade 1 were included. Further, we identify increased Ki-67 labeling as a strong predictor of
poor OS from MPNST. Finally, we identify a subset of MPNSTs with a predictive immunohistochemical profile that
has improved local control with adjuvant radiotherapy. These data provide insights into the grading and therapy
for patients with MPNST, although further studies are needed for independent validation.

Key Points
• Our results corroborate the validity of the FNCLCC sarcoma grading criteria as a
prognostic scheme for MPNST.
• We identify a subset of MPNSTs with a distinct immunophenotypic profile that have
improved local control with adjuvant radiotherapy.
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Importance of the Study

Malignant peripheral nerve sheath tumor (MPNST) is an
aggressive and rare neoplasm involving peripheral nerves
and extraneural soft tissues. MPNST represents 5% of soft
tissue sarcomas, with an incidence of 0.2 cases per 100,000
persons each year in the United States.1–3 They exhibit
Schwann or perineurial cell differentiation and are classically sporadic, associated with neurofibromatosis type 1
(NF1), or prior radiotherapy.4 Treatment options for patients
with MPNST are limited, and their clinical course is marked
by high metastatic risk and poor overall prognosis.1,5–12
Surgical resection is the mainstay of MPNST treatment, with
ionizing radiation and chemotherapy primarily reserved
for high risk features—such as large size, deep location, or
subtotal resection—unresectable disease, or salvage treatment.1,5–7,10,13–17 However, due to the rarity of MPNST, optimal treatment paradigms remain controversial. Thus,
there is an urgent, unmet need for prognostic and predictive
markers to identify patients who may benefit from adjuvant
therapy.
MPNST is mostly a hypercellular spindled cell
tumor with fusiform nuclei arranged in streaming and
intersecting fascicles, histologically mimicking various
sarcomas, spindle cell melanomas, and poorly differentiated carcinomas. Neural crest differentiation can be confirmed using immunohistochemical (IHC) markers such
as SOX10 or S100, but these have limited diagnostic sensitivities and specificities, often being lost in MPNST18
and expressed to various degrees in many other tumors.
Thus, the diagnosis of MPNST is often predicated on
exclusion of other spindle cell neoplasms through an
extensive IHC panel. Moreover, the distinction of malignant transformation of peripheral nerve sheath tumors
in patients with NF1 is dependent on integration of various clinicopathologic findings, and no highly sensitive
and specific biomarkers are available.19 Further, few
immunohistochemical markers are prognostic and none
are currently used to inform treatment paradigms for
MPNST patients. Interestingly, the Fédération Nationale
des Centres de Lutte Contre le Cancer (FNCLCC) grading
system has been proposed to risk-stratify sarcomas, although its prognostic value for MPNST is debated.20,21
Grading is not currently included in diagnostic reports
at many institutions, although the fifth edition WHO
Classification of Soft Tissue and Bone Tumours implies
prognostic significance to histologic grade.22
Here, we describe a retrospective series of 54 patients diagnosed with MPNST at a single institution with
comprehensive histopathologic characterization and

for MPNST patients. Thus, there is an urgent,
unmet need for prognostic and predictive markers
to identify patients who may benefit from adjuvant therapy. These data provide insights into the
grading, immunohistochemical markers, and adjuvant treatment for patients with MPNST, shedding light on MPNST biology and treatment.

clinical follow-up. We report long-term outcomes, prognostic markers, and a predictive classification scheme to
identify MPNST patients who are most likely to benefit
from adjuvant radiotherapy.

Methods
Patient Cohort and Tumor Characteristics
This is a retrospective cohort study of patients who were
treated for MPNST between 1990 and 2018 at a single
center. Fifty-four consecutive patients were included in this
study. Inclusion criteria were UCSF patients with available
pathology materials and clinical follow-up. Pathology material for all cases was reviewed for diagnostic accuracy
and various histologic features outlined below. Tumors in
which melanoma was a consideration, neoplasms in which
sarcoma diagnoses (eg, fibrosarcoma, fibromyxoid sarcoma, and leiomyosarcoma) remained in the differential,
and nerve sheath tumors with equivocal features of malignancy were excluded based on consensus review between
an expert soft tissue pathologist (A.E.H.) and board-certified
neuropathologists (A.P. and M.P.). Tumors were categorized
using the FNCLCC system grading criteria as a composite
of tumor differentiation, necrosis, and mitotic count scores
as previously described.20 Tumor differentiation was scored
on a scale of 1–3 based on the most prominent morphology
on H&E-stained sections as follows: well-differentiated peripheral nerve sheath tumor such as neurofibroma-like morphology with cytologic atypia and increased mitotic activity
(1); monomorphic spindle cell neoplasm with intersecting
fascicles with moderate atypia and at least focal suggestion
of morphologic Schwannian differentiation (2); and undifferentiated pleomorphic sarcoma-like morphology without
any morphologic Schwannian differentiation, and/or those
with a rhabdomyosarcomatous component (3). Necrosis
was scored on a scale of 0–2 based on total area of available
diagnostic material: no necrosis (0), less than 50% tumor necrosis (1), and greater than or equal to 50% tumor necrosis
(2). Mitotic count was performed in the most proliferative
tumor focus across a contiguous area of approximately
2 mm2 (roughly 10 high-power fields at 400× magnification)
and scored on a scale of 1–3: 0–9 mitoses (1), 10–19 mitoses
(2), and 20 or more mitoses (3). The overall grade was calculated from a sum of the tumor differentiation, necrosis, and
mitotic count scores: FNCLCC Grade 1 (total score of 2 or 3),
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IHC was performed using formalin-fixed, paraffinembedded tissue sections on a combination of whole
slide sections and tissue microarrays using the following
antibodies: Ki-67 (Ventana, clone 30–9, 1:1 dilution),
trimethylated lysine 27 on histone-H3 i.e. H3K27me3 (Cell
Signaling Technology, clone C36B11, 1:50 dilution), SOX2
(EMD Millipore, clone AB5603, 1:200 dilution), SOX10
(Cell Marque, 1:50 dilution), p16 (Santa Cruz, clone JC8,
1:50 dilution), p53 (Dako, clone DO-7, 1:50), epidermal
growth factor receptor, that is, EGFR (Ventana, clone 3C6,
1:20 dilution), p75NTR (Abcam, clone NGFR5, 1:100 dilution), S100 (Ventana, 1:2 dilution), and Neurofibromin
(DKFZ, clone NFC, 1:4 dilution). All immunostaining was
performed on Ventana Benchmark XT automated stainer
(Roche Diagnostics) using standard techniques.18 IHC
studies that were previously performed as part of clinical
diagnostic workup, or stains obtained as part of prior research studies were also reviewed.18,23 Percent staining for
H3K27me3, SOX2, SOX10, p16, p53, EGFR, p75NTR, S100,
and Neurofibromin was estimated as the percentage of
positive tumor cells on available stained tissue. H3K27me3
staining was also dichotomized as “retained” and “complete loss,” with the latter defined as staining in less than
5% of tumor cells in the presence of internal positive control. The Ki-67 proliferation index was estimated as percentage of positive nuclei in the area of highest labeling
across an area of approximately 2 mm2 (10 high-power
fields at 400× magnification). Ki-67 values greater than the
median labeling value of this cohort (60%) were classified
as “significantly elevated.”

Statistical Analysis
Locoregional failure-free rate (LFFR), metastasis-free survival (MFS), and overall survival (OS) were estimated using
the Kaplan–Meier method and visualized in GraphPad
Prism. LFFR was defined as the time to local recurrence in
the setting of a gross total resection or local progression
in the setting of a subtotal resection based on increased
size on surveillance imaging. MFS was defined as time to
a radiographically identified metastasis. Survival analysis
including the log-rank test and Cox Proportional Hazards
(CPH) regression were computed using the “survival”
package in R. Variables reaching P < .1 on univariate analysis using the log-rank test were included in multivariate
analysis.
Hierarchical clustering of IHC staining percentages per
sample was performed using the “heatmaply” package in
R, with default setting and ward linkage. The differences

Results
A summary of the patient characteristics within our cohort is provided in Table 1. Our cohort consisted of 24
male (44%) and 30 female (56%) patients. The median
age of MPNST patients at the time of initial diagnosis
was 38 years (range 5–83), and 32 patients (59%) had a
  
Table 1. Patient and Tumor Characteristics of 54 Patients With
MPNST
Variable
Sex
Age

Value/n

%

Male

24

44

Female

30

56

Median

38

-

Min

5

Max

83

Clinical Neurofibromatosis
Type 1

Yes

32

59

No

22

41

Tumor location

Head and neck

9

17

28

52

Trunk
Upper extremities
Tumor dimensions (cm)

7

13

Lower extremities 10

18

Median

-

Min

8
0.5

Max

26

Prior history of radiation
therapy

Yes

2

4

No

52

96

Neoadjuvant chemotherapy

Yes

3

6

No

51

94

Yes

25

46

No

29

54

Yes

16

30

No

38

70

Sub total

16

30

Gross total

38

70

Negative

20

41

Positive

29

59

Adjuvant radiation therapy
Adjuvant chemotherapy
Extent of resection
Margin status

n/a
FNCLCC grade

Modified FNCLCC grade

5

-

Grade 1

6

11

Grade 2

16

30

Grade 3

32

59

Low grade

22

41

High grade

32

59

FNCLCC, Fédération Nationale des Centres de Lutte Contre Le Cancer;
MPNST, Malignant peripheral nerve sheath tumor.
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Immunohistochemistry

between mean percentage staining of each IHC stain between identified clusters was tested for significance using
the nonparametric Mann–Whitney U test (Wilcoxon ranksum test). Unless specified, all tests used were 2-tailed.
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FNCLCC Grade 2 (total score of 4 or 5), and FNCLCC Grade 3
(total score of 6, 7, or 8). An additional 2-tier grading system
was generated with tumors dichotomized in to low-grade
(FNCLCC Grade 1 and Grade 2 tumors; total score of 5 or
less) and high-grade (FNCLCC Grade 3 tumors; total score
of 6 or more) using the above mentioned FNCLCC criteria.
The Institutional Review Board, Human Research Protection
Program Committee at the University of California San
Francisco approved this study (CHR# 18-24633).
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of necrosis was associated with worse OS (P = .0001) and
MFS (.03). There was no difference in OS or MFS based on a
necrosis score of 1 versus 2 on univariate analysis (P = .80
and P = .40, respectively). Higher mitotic activity score was
associated with worse OS (P = .04), but there was no association between mitotic activity score and MFS. LFFR
was not associated with any of the FNLCC components.
Immunohistochemically, significantly elevated Ki-67 labeling index (defined as greater than the cohort median
of 60%; Figure 2C–C’; P = .0002) was associated with significantly worse OS. Similarly, on univariate CPH analysis,
increasing Ki-67 labeling index was associated with poor
OS (HR 1.36 per 10%, P = .0002) and trended toward worse
MFS (HR 1.2 per 10%, P = .07). Loss of H3K27me3 was not
associated with OS (P = .2), MFS (P = .8), or LFFR (P = .5).
To identify prognostic variables for LFFR, MFS, and OS,
we performed multivariate CPH analysis using variables
with P values <.1 on univariate analysis, excluding the separate FNCLCC categories (Table 2). For LFFR, multivariate
analysis revealed a trend toward improved outcomes for
both adjuvant radiotherapy (P = .07) and gross total resection (P = .09). For MFS, only male sex remained significantly associated with poor MFS (P = .02) on multivariate
analysis. Ki-67 labeling index remained a significant independent parameter associated with poor OS on multivariate analysis (P = .02). Taken together, these results identify
adjuvant radiation therapy and resection status as important parameters in achieving local control and suggest that
high Ki-67 index can be used as a histologic surrogate to
predict OS.
Finally, we hypothesized that examining a more diverse array of IHC stains targeting numerous proteins
involved in various pathways implicated in MPNST biology may outperform any single stain and potentially
identify prognostic and predictive immunohistochemical
signatures.23–31 To that end, we performed staining for
H3K27me3, EGFR, SOX2, p75NTR, S100, SOX10, p53,
p16, and Neurofibromin on MPNSTs with sufficient
available tissue and quantitatively scored the stains as
percent positive tumor cells (n = 35). Unsupervised hierarchical clustering based on this larger IHC panel
identified 2 subgroups of tumors (Figure 3A). Cluster
1 (n = 11) was characterized by retention of H3K27me3
and Neurofibromin staining, relative increased S100,
SOX10, and p16 immunoreactivity, and relatively limited
EGFR staining (Figure 3B). In contrast, Cluster 2 (n = 24)
was characterized by decreased Neurofibromin (7% vs
80%, P = 4.7E−06), H3K27me3 (17% vs 92%, P = 2.7E−05),
SOX10 (3% vs 28%, P = .001), S100 (13% vs 55%, P = .01),
and p16 staining (3% vs 34%, P = .07), as well as increased
EGFR staining (56% vs 21%, P = .01) and higher Ki-67 labeling (64% vs 42%, P = .02) (Supplementary Figure S1;
Supplementary Table S2). Consistent with IHC results, clinical NF1 status was the only clinical characteristic that differed between subgroups, with Cluster 2 enriched for NF1
patients (Supplementary Table S3). With regard to clinical
outcomes, no significant differences were observed between clusters with regard to OS (Figure 3C; P = .15) or
LFFR (Figure 3D; P = .96). However, to determine whether
MPNST clusters harbored predictive utility, we compared
responses to adjuvant therapy between subgroups. While
there was no difference in response to chemotherapy
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clinical diagnosis of NF1. Two patients (4%) had prior radiation treatment to the tumor sites for unrelated causes,
both 19 years prior to the diagnosis of MPNST, suggestive of radiation-induced MPNST. Three patients (6%) received neoadjuvant chemotherapy. A total of 16 patients
(30%) underwent subtotal resection, and the remaining
38 patients (70%) underwent gross total resection. Margin
status was assessed in 49 cases (5 cases of piecemeal resection were excluded), with positive margins in 29 (59%)
and negative margins in 20 (41%) patients. Postoperative
therapy was delivered at the discretion of the treating
physician, with a total of 25 patients (46%) receiving adjuvant radiotherapy and 16 patients (30%) receiving
adjuvant chemotherapy. A summary of patient characteristics sorted by adjuvant radiotherapy status is provided
in Supplementary Table S1. Tumor location was the only
baseline characteristic that differed between patients who
received adjuvant radiotherapy and patients who did not
(P = .02). By FNCLCC grading criteria, there were 6 Grade
1 (11%), 16 Grade 2 (30%), and 32 Grade 3 (59%) tumors
in our cohort. Using a modified 2-tier FNCLCC grading
scheme, there were 22 lower-grade tumors (41%) and 32
high-grade tumors (59%). Histologically, tumors demonstrated haphazardly arranged elongate cells with varying
degrees of nuclear atypia, consistent with a diagnosis of
MPNST (Figure 1A–A’).
In our cohort, 5-year OS was 58% (Figure 1B), 5-year MFS
was 68% (Figure 1C), and 5-year LFFR was 66% (Figure 1D).
Patients who received adjuvant radiotherapy demonstrated no significant benefit with regard to OS (Figure 1E;
P = .5) or MFS (Figure 1F; P = .4), but adjuvant radiotherapy
improved LFFR (Figure 1G; P = .05). Patients who received
adjuvant chemotherapy demonstrated no significant
benefit to OS (P = .3), MFS (P = .2), or LFFR (P = .9). There
were no significant differences between NF1-associated
and sporadic MPNSTs for OS (Figure 1H; P = .44), MFS
(Figure 1I; P = .90), or LFFR (Figure 1J; P = .33). On univariate CPH analysis for these baseline clinical parameters
(Table 2), increased tumor size was significantly associated
with poor MFS (hazard ratio [HR] 1.09 per cm, P = .01) and
poor OS (HR 1.07 per cm, P = .03), male sex was associated
with poor MFS (HR 6.23, P = .002), and gross total resection (HR 0.37, P = .06) and adjuvant radiotherapy (HR 0.36,
P = .05) trended toward improved LFFR.
We next explored histopathologic and IHC characteristics within our cohort. FNCLCC grading was performed
as mentioned above across a histologically diverse spectrum of MPNST (Figure 2A). FNCLCC grade segregated
patients into groups with significant differences in OS
(Figure 2B; P = .02, log-rank test). Of note, FNCLCC grade
1 tumors appeared to have both improved OS and a trend
toward improved MFS on univariate analysis, although
there were only 6 cases meeting this histologic criterion.
We generated a 2-tier system combining grades 1 and 2 as
“lower-grade” and assigning grade 3 as “high-grade,” and
showed that patients with high-grade tumors have worse
MFS (P = 0.02) and OS (Figure 2B’; P = .01) compared with
patients with low-grade tumors. We then evaluated the
components of the FNCLCC grading separately (Table 3)
and showed that tumor differentiation score of 1 trended
toward better OS (P = .07), and tumor differentiation score
of 3 was associated with worse MFS (P = .03). Presence
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Figure 1. Malignant peripheral nerve sheath tumor (MPNST) clinical outcomes. Representative H&E images of MPNSTs at (A) low and (A’)
high magnification. Kaplan–Meier curves for all patients in the MPNST cohort shows (B) overall survival (OS), (C) metastasis-free survival,
and (D) locoregional failure-free rate. (E) OS, (F) metastasis-free survival, and (G) locoregional failure-free rate (LFFR) based on adjuvant
radiation therapy reveals significant improvement in LFFR associated with radiation (P = .05). (H) OS, (I) metastasis-free survival, and (J)
locoregional failure-free rate based on based on clinical NF1 status reveals no significant differences in patients with NF1-associated
MPNST.
  

with regard to LFFR, MFS, or OS (data not shown), we
found cluster status was predictive of response to radiation in our cohort. Although Cluster 1 patients appeared

to have no LFFR benefit with adjuvant radiotherapy
(Figure 3E; P = .83), Cluster 2 patients who received adjuvant radiotherapy showed significantly improved LFFR
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Bold, P < 0.1. FNCLCC, Fédération Nationale des Centres de Lutte Contre Le Cancer; GTR, gross total resection; MPNST, Malignant peripheral nerve sheath tumor; LFFR, locoregional failure-free rate; MFS,
metastasis-free survival; MVA, multivariate analysis; OS, overall survival; UVA, univariate analysis.
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1.001 (0.35–2.89)

UVA - MFS
HR

P-value
(Log-rank)

UVA - LFFR

HR

Univariate and Multivariate Cox Proportional Hazards Analysis for Clinical and Histopathologic Features

Male
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B

100 µm

B’
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p = .02
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Grade 3
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0
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6
No. at risk: 16
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6
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23

Overall survival (%)

80
60

p = .01
Low grade
High grade

40
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0

0

C

100 µm

100
Overall survival (%)

Overall survival (%)

100

40

Grade 3

60
90
Time (months)
6
9
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100
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0

30

4
5
7
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32

17
23

5
8
9
Ki-67 <60%
Ki-67≥60%

80

C’

60
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Time (months)

Ki-67 Index < 60%
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9
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9
7

Ki-67 Index ≥ 60%

60
p = .0002
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0

No. at risk:
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27
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9
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6
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120
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Figure 2. Malignant peripheral nerve sheath tumor (MPNST) clinical outcomes stratified by immunohistochemical staining and Fédération
Nationale des Centres de Lutte Contre Le Cancer (FNCLCC) grade. (A) Overall survival (OS) based on FNCLCC grade with (A) representative images
of FNLCC grades 1, 2, and 3. OS based on (B) 3-tier FNCLCC grade and (B’) 2-tier modified FNCLCC grade. OS based on (C) Ki-67 labeling index with
(C’) representative images of Ki-67 <60 versus Ki-67 ≥ 60.
  

(Figure 3F; P = .004). Thus, our data broadly suggest that
immunohistochemical profiles are prognostic and predictive for MPNST outcomes and incorporating these
staining patterns into clinical decision-making may help
guide treatment of MPNST patients.

Discussion
Here, we report a single-institution MPNST experience
with comprehensive clinical follow-up and histopathologic
characterization. In this cohort, outcomes are similar to
previously reported cohorts, with long-term OS of ~50%
and high rates of metastasis and local failure.14,16,32–34
While adjuvant radiotherapy does not appear to affect OS
or MFS, we demonstrate a trend toward improved LFFR
with adjuvant radiotherapy. From a clinical perspective,
MPNSTs arising in patients with a clinical NF1 diagnosis

do not show significant differences in outcome, but univariate regression analysis did identify clinical factors associated with differences in MFS (male sex and tumor size) and
OS (tumor size).
From a histopathologic perspective, univariate analysis
demonstrates that increased grade, as determined by current FNCLCC criteria or using a modified 2-tier system, correlates with poor MFS and OS in MPNST. FNCLCC grading
has been shown to be a reliable predictor of metastatic potential in many soft tissue tumors. However, in a review of
1240 patients with soft tissue sarcomas, FNCLCC grading
did not show any significant predictive value in a subset
of 72 MPNSTs.20 Other contemporary series have shown
conflicting data regarding the prognostic significance of
FNCLCC grading in MPNST.15,35,36 Thus, the current recommendation by the College of American Pathologists is
to not employ the FNCLCC grading scheme in MPNSTs.
While our cohort is relatively small, especially for tumors
on the lower end of the grading scheme, our findings lend
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Table 3.

Univariate Cox Proportional Hazards Analysis for FNCLCC Categories
UVA - LFFR

UVA - MFS

UVA - OS

P-value
(Log-rank)

HR

P-value
(Log-rank)

HR

P-value
(Log-rank)

2 vs 1

2.13 (0.24–18.68)

.7

5.0e7 (0-Inf)*

.4

7.0e8 (0-Inf)*

.07

3 vs 1

1.17 (0.13–10.29)

.9

1.6e8 (0-Inf)*

.2

9.6e8 (0-Inf)*

.14

FNLCC Differentiation

3 vs 2

0.55 (0.18–1.71)

.3

3.17 (1.08–9.32)

.03

1.37 (0.63–2.98)

.4

FNLCC differentiation - continuous

0.83 (0.39–1.79)

.6

3.48 (1.25–9.69)

.01

1.82 (0.94–3.54)

.07

1 vs 0

1.58 (0.52–4.80)

.4

2.63 (0.69–10.09)

.1

8.96 (2.08–38.60

.0004

2 vs 0

0.67 (0.08–5.74)

.7

4.60 (1.00–21.18)

.03

8.19 (1.58–42.57)

.001

2 vs 1

0.44 (0.06–3.57)

.4

1.67 (0.48–5.81)

.4

0.86 (0.43–3.14)

.8

Necrosis - present or absent

1.59 (0.53–4.71)

.4

3.58 (0.99–12.94)

.03

10.4 (2.45–44.4)

.0001

2 vs 1

0.70 (0.06–7.77)

.9

2.86 (0.26–31.60)

.35

2.17 (0.36–13.02)

.3

3 vs 1

2.58 (0.57–11.66)

.2

4.14 (0.54–32.02)

.15

3.78 (0.89–16.16)

.07

3 vs 2

3.92 (0.50–30.81)

.2

1.44 (0.32–6.47)

.64

1.74 (0.51–5.89)

.4

FNLCC mitosis- continuous

1.80 (0.82–3.94)

.1

1.87 (0.80–4.37)

.1

1.90 (.0–3.61)

.04

Mitoses/10hpf - continuous

1.01 (0.99–1.03)

.4

1.01 (0.99–1.04)

.4

1.01 (0.99–1.03)

.1

FNLCC Necrosis

FNLCC Mitosis

Bold, P < 0.05. FNCLCC, Fédération Nationale des Centres de Lutte Contre Le Cancer; MPNST, Malignant peripheral nerve sheath tumor; LFFR,
locoregional failure-free rate; MFS, metastasis-free survival; OS, overall survival; UVA, univariate analysis.

  
support to the use of FNCLCC grading criteria as a clinically prognostic score that may contribute to clinical decision-making in the treatment of individuals with MPNST.
Although mitotic score calculated by FNCLCC criteria was
associated with poor OS, proliferation index calculated by
Ki-67 labeling appears to be a better prognostic marker of
OS on univariate and multivariate analysis. Increased Ki-67
labeling index was one of the first reported independent
prognostic IHC markers for MPNST.37,38 While benign peripheral nerve sheath tumors such as schwannomas or
neurofibromas may show an increased mitotic rate, the
Ki-67 labeling index is significantly elevated in MPNST
compared to benign peripheral nerve sheath tumors.18,37,39
Our results reiterate the predictive value of Ki-67 labeling
as an independent prognostic marker for OS in MPNST.
Unsupervised
hierarchical
clustering
of
immunohistochemical profiles identifies 2 MPNST
subgroups with significant differences in H3K27me3,
Neurofibromin, S100, SOX10, p16, EGFR, and Ki-67 labeling. Cluster 2 shows significant loss of H3K27me3,
Neurofibromin, S100, SOX10, and p16 labeling, with
increased EGFR and Ki-67 labeling when compared
with Cluster 1. Loss-of-function mutations in the genes
encoding polycomb repressive complex 2 (PRC2) subunits
EED and SUZ12 have been reported as oncogenic drivers
in MPNST.40,41 PRC2 is a histone-modifying complex that
functions as a protein lysine methyltransferase responsible for producing H3K27me3 which is often a repressive
transcriptional mark.42 Complete loss of the H3K27me3
signature by IHC has been reported as a moderately sensitive and relatively specific marker for the diagnosis of

MPNST.23,25–27,30 In addition to use as a candidate diagnostic
marker, loss of H3K27me3 has been shown to have prognostic significance. Patients with MPNSTs that have loss
of H3K27me3 have inferior survival compared with patients with MPNSTs that have intact H3K27me3.26 While
we did note a spectrum of H3K27me3 labeling in our cohort of MPNST patients, we did not find a significant association between the retention of H3K27me3 staining
and LFFR, MFS, or OS on univariate analysis. However,
Cluster 2 (the group with decreased H3K27me3 labeling)
exhibits improved LFFR associated with adjuvant radiotherapy while Cluster 1 did not show any benefit from adjuvant radiotherapy. While H3K27me3 status in isolation may
not be a significant predictor of outcomes, integration of
immunohistochemical results in MPNST may help predict
response to adjuvant radiotherapy and help to stratify patients into different treatment paradigms.
In addition to decreased H3K27me3, Cluster 2 is characterized by decreased labeling with Neurofibromin as well
as the lineage markers SOX10 and S100 and cell cycle
regulator p16. Neurofibromin is a GTPase-activating protein encoded by NF1 and is involved in various cell proliferation and differentiation pathways in neural crest
and mesenchymal stem cell–derived tissues.43 Loss of
immunoreactivity of Neurofibromin has been reported
in MPNST and implies dysregulation of protein production or expression.24 SOX10 is a transcription factor that
regulates neural crest multipotency and is necessary for
Schwann cell and melanocyte differentiation.44,45 Similarly,
the S100 family of proteins are expressed in neural crest
derived cells and immunoreactivity for S100 is often used
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Figure 3. Malignant peripheral nerve sheath tumor (MPNST) clinical outcomes stratified by immunohistochemical clustering. (A) Hierarchical
clustering heatmap of immunohistochemical (IHC) stains (x-axis) in MPNSTs (y-axis). (B) Histogram of IHC labeling distribution based on cluster.
(C) Overall survival (OS) based on cluster. (D) Locoregional failure-free rate based on cluster. (E) OS for Cluster 1 stratified by adjuvant radiation
therapy. (F) Locoregional failure-free rate for Cluster 2 stratified by adjuvant radiation therapy.
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